{"nctId":"NCT02408315","briefTitle":"Induction With Misoprostol: Oral Mucosa Versus Vaginal Epithelium (IMPROVE)","startDateStruct":{"date":"2015-09"},"conditions":["Pregnancy"],"count":300,"armGroups":[{"label":"misoprostol/placebo using buccal","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: misoprostol/placebo"]},{"label":"misoprostol/placebo using vaginal","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: misoprostol/placebo"]}],"interventions":[{"name":"misoprostol/placebo","otherNames":["Cytotec"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* A medical indication for induction of labor at a gestational age between 37 +0 and 38 +6 weeks OR an elective or medical indication for induction of labor at a gestational age greater than or equal to 39 + 0 completed weeks\n* Participant age of greater than or equal to14 years old\n* Singleton pregnancy\n* Modified Bishop score of less than or equal to 6\n* Vertex fetal presentation by examination or ultrasound\n* Any membrane status\n\nExclusion Criteria:\n\n* Elective inductions between 37 +0 and 38 +6 completed weeks are specifically excluded\n* Known intrauterine fetal demise\n* Any uterine scar including prior cesarean section and myomectomy\n* Known major fetal congenital malformations that may impact neonatal health\n* Other evidence of fetal compromise (such as Category 2 or 3 tracing) before the induction begins\n* Prior induction/cervical ripening methods utilized during this pregnancy\n* Allergy to misoprostol\n* Known untreated cervical infection (e.g. Gonorrhea, Chlamydia)\n* Planned cesarean section due to maternal or fetal condition\n* Any other contraindication to labor induction or misoprostol therapy","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"14 Years","maximumAge":"45 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Time to Delivery","description":"number of hours from placement of study drug to delivery\n\nCesarean delivery for fetal non--reassurance indication","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28.1","spread":null},{"groupId":"OG001","value":"20.1","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Cesarean Deliveries Based on Fetal Non-Reassurance Indications","description":"Rate of cesarean deliveries performed for fetal non-reassurance as the indication","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Vaginal Deliveries That Occurred Within 24 Hours","description":"rate of achieving vaginal delivery within 24 hours","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"58","spread":null},{"groupId":"OG001","value":"89","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who Had Uterine Hyperstimulation","description":"Presence of uterine hyperstimulation, tachysystole as defined as 6 uterine contractions in a 10 minute period","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"22","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Neonatal Intensive Care Unit (NICU) Admission","description":"Admission to NICU","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30","spread":null},{"groupId":"OG001","value":"31","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Doses Misoprostol Used","description":"Number of doses of misoprostol needed","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Uterine Rupture","description":"Presence of uterine rupture","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Dose of Oxytocin Used for Augmentation","description":"dose of oxytocin used for augmentation of labor","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Neonatal Cord Gases Measured","description":"cord gases from newborn","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Pharmacokinetic Profiling of Misoprostol","description":"pharmacokinetic parameters (Area under the curve, half-life, maximum concentration) measured over first 2 study drug doses","paramType":null,"dispersionType":null,"classes":[]},{"type":"OTHER_PRE_SPECIFIED","title":"Participant Satisfaction","description":"participant satisfaction with labor induction and preference for method of drug administration. This will use a questionnaire developed for this study with some similarity to the referenced Nassar study below.","paramType":null,"dispersionType":null,"classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":11,"n":148},"commonTop":["Any Maternal or Fetal Event"]}}}